China’s National Medical Products Administration has given the green light to Innovent Biologics, Inc.’s and Jiangsu Aosaikang Pharmaceutical Co. Ltd.’s NDA for third-generation EGFR tyrosine kinase inhibitor limertinib, for treating adults with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer.
Researchers have developed an innovative immunotoxin (a fusion protein called GrB-Fc-KS49) designed to target epithelial membrane protein-2 (EMP2), a biomarker overexpressed in more than 75% of breast cancer cases, including triple-negative breast cancer (TNBC).
It is known that mitochondrial unfolded protein response (UPRmt), initiated by the transcription factor ATF5, maintains protein homeostasis under stress conditions by folding denatured proteins, folding newly imported proteins into the mitochondria or by degrading damaged proteins.
Anges Inc. has entered into a sponsored research agreement with Stanford University School of Medicine for the development of novel cancer therapies using genome editing technology. The parties aim to combine nucleic acid drug delivery technology developed at Stanford with the genome editing technology of Emendobio Inc., a subsidiary of Anges.
The membrane-associated tyrosine/threonine protein kinase 1 (PKMYT1) regulates cell cycle progression and maintains genomic integrity. If it is dysregulated, cells may enter mitosis prematurely, potentially initiating tumorigenesis.
Immunoforge Co. Ltd.’s approval of an IND by the Korea Ministry of Food and Drug Safety reminded Wall Street – not that anybody needed reminding – about the marketplace jostle among therapies for chronic myeloid leukemia (CML), where a number of drugs are cleared by the U.S. FDA but significant need remains in terms of efficacy as well as tolerability.
Bristol Myers Squibb Co. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a DNA-binding protein Ikaros (IKZF1)-, zinc finger protein Helios (IKZF2)-, Aiolos (IKZF3)- and Eos (IKZF4)-targeting moieties through a linker.
Work at IFM Due Inc. has led to the identification of stimulator of interferon genes protein receptor (STING; TMEM173) antagonists reported to be useful for the treatment of cancer, systemic lupus erythematosus, autoinflammatory interferonopathy, rheumatoid arthritis and Aicardi-Goutieres syndrome.
Trophoblast cell surface antigen 2 (TROP2) is a transmembrane glycoprotein that acts as an intracellular calcium signal transducer, frequently overexpressed in cancer and associated with poor prognosis and disease recurrence.
RSS
